Find a Lawyer
Xarelto® Lawsuit Update - Plaintiffs' Claims Supported by Scientific Studies

Xarelto® Lawsuit Update - Plaintiffs' Claims Supported by Scientific Studies


Xarelto® is a prescription anticoagulant medication that is intended to treat patients who are at an increased risk for developing dangerous blood clots due to various medical conditions. The medication is commonly recommended for patients suffering from deep vein thrombosis, pulmonary embolism, atrial fibrillation, and those who require hip or knee replacement surgeries. However, an increased incidence of patients experiencing uncontrolled bleeding events has prompted an influx of claims in the Xarelto® lawsuit. Recently, while bellwether trials have been scheduled in Louisiana, plaintiffs have been using a number of scientific studies to support their legal claims. If you have experienced any adverse side effects after being prescribed the drug and would like more information about the Xarelto® lawsuit update, please contact our legal team to schedule a free case evaluation.

Scientific Studies Supporting Plaintiffs' Claims

Plaintiffs in the Xarelto® lawsuit have been citing scientific studies published in peer-reviewed journals to support their claims. An article in the Journal of the American Medical Association Ophthalmology (JAMA Ophthalmology) from October 2015 found a correlation between Xarelto® use and spontaneous vitreous hemorrhage (internal bleeding of the eye). Researchers Judy Hun and John Hwang found an increase incidence of the bleeding event in their patients, and concluded that the risk of hemorrhage may be particularly elevated during the transition period from traditional anticoagulants to Xarelto®.

Xarelto® plaintiffs are also indicating the conclusions published in the British Medical Journal in April 2015 concerning a study on the risk of gastrointestinal bleeding associated with Xarelto® and other similar anticoagulant medications. Researchers from John Hopkins and George Washington University found a nearly doubled incidence of internal bleeding with Xarelto® when compared to Warfarin, the traditional pharmaceutical therapy for patients at risk for blood clots. 

Primary Bellwether Trials Scheduled

The first four bellwether trials have been scheduled in Eastern Louisiana under Presiding Judge Eldon Fallon, who has been assigned as the administrator of the current multidistrict litigation (MDL) action in the state. The majority of cases across the country have been consolidated under MDL to expedite the evidence discovery process and allow consistent rulings for common issues among the separate claims. The first of the four bellwether trials will be heard in February 2017, with the next three trials set to open in the following three months.

Arrange a Complimentary Consultation

Members of our legal team are currently investigating claims in the Xarelto® lawsuit. If you have been prescribed the drug and experienced an uncontrolled breeding event, please contact an experienced pharmaceutical attorney.